Biogen Inc. (BIIB) は上場企業です ヘルスケア セクターの 製薬 業界で事業展開. 本社所在地は Cambridge, MA, アメリカ. 現CEOは Christopher A. Viehbacher.
BIIB を有する IPO日 1991-09-17, 7,605 名の正社員, に上場 NASDAQ Global Select, 時価総額 $26.26B.
Biogen Inc. is a global biopharmaceutical company founded in 1978 and headquartered in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for neurological and neurodegenerative diseases. The company maintains a robust portfolio of approved treatments across multiple therapeutic areas, including multiple sclerosis (TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, OCREVUS), spinal muscular atrophy (SPINRAZA), Alzheimer's disease (ADUHELM), and oncology and immunology indications (RITUXAN, GAZYVA), alongside a growing biosimilar franchise featuring etanercept, adalimumab, and infliximab biosimilars. Beyond its marketed products, Biogen maintains an extensive pipeline of investigational therapies targeting neurological disorders, including candidates for multiple sclerosis, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease, and immunology-related conditions. The company leverages strategic collaborations with leading pharmaceutical and biotechnology partners including Genentech, Eisai, Ionis Pharmaceuticals, and Sage Therapeutics to advance its research and development initiatives across its core therapeutic focus areas.
